Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15660484 | 0.98 | GAA (0.41) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL15659112 | 0.98 | GAA (0.41) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL15657877 | 0.98 | GAA (0.41) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL15658141 | 0.95 | GAA (0.41) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL29100398 | 0.90 | TLR8 (0.40) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL15657108 | 0.88 | MAPT (0.40) | TLR8GAAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL15656771 | 0.85 | GAA (0.42) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL478253 | 0.84 | CNR1 (0.39) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL7171433 | 0.84 | GAA (0.34) | TLR8GAAALDH1A1KDM4ENPC1 | |
| SCHEMBL15657848 | 0.84 | KDM4E (0.43) | TLR8GAAALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735581-B1 | COMPOSITION AND POLYMER | ASAHI CHEMICAL IND (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-9738757-B2 | Composition and polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160222168-A1 | Composition and Polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-08-04 | — | — | US | disclosed |
| US-9334371-B2 | Composition and polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-05-10 | — | — | US | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150087618-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| EP-2735581-A1 | COMPOSITION AND POLYMER | Asahi Kasei Chemicals Corporation (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-20030225297-A1 | Process for preparing chiral diphosphines | RHODIA CHIMIE | 2003-12-04 | — | — | US | disclosed |
| US-6610875-B1 | Forming bidentate ligands ofr assymetric catalysts; bromina-ting diaryldiol; esterifying with sulfonic acid; substituting cyano for bromine groups; coupling with a dicyclophosphine | RHODIA CHIMIE (FR) | 2003-08-26 | — | — | US | disclosed |
| US-6184415-B1 | ASYMMETRIC HYDROGENATION OF A 2-HALO(ELECTRONEGATIVE)ALKENOIC ACID/SALT (2-HALOACRYLIC ACID OR SALT), USING AN ENANTIOMETRICAL RICHED CATALYST OF 2,2'-BIS(DIARYLPHOSPHINO-PHINO-1,1'-BINAPHTHYL COMPLEX OF RUTHENIUM; HALIDE PROMOTERS | ALBEMARLE CORPORATION | 2001-02-06 | — | — | US | disclosed |
| EP-0738254-B1 | ASYMETRIC HYDROGENATION OF BETA- or GAMMA-KETOESTERS AND BETA- or GAMMA-KETOAMIDES | MERCK & CO INC (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5596113-A | HYDROGENATION CATALYSTS | MERCK & CO., INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5508435-A | ASYMMETRIC REDUCTION WITH A RUTHENIUM CATALYST IN PRESENCE OF A STRONG ACID | MERCK & CO., INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5202473-A | Hydrogenation of a-arylpropenoic acid | MONSANTO COMPANY (US) | 1993-04-13 | — | — | US | disclosed |
| EP-0536105-A1 | Ruthenium(II)-binap diketonate complexes | MONSANTO COMPANY (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5198561-A | Phosphine complexes with ruthenium | MONSANTO COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| US-5144050-A | Hydrogenation Catalysts | MONSANTO COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TLR8 2394/4885GAA 223/4885ALDH1A1 2858/4885 |
| US-20150087618-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TLR8 2394/4885GAA 223/4885ALDH1A1 2858/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TLR8 2394/4885GAA 223/4885ALDH1A1 2858/4885 |
| US-20030225297-A1 | Process for preparing chiral diphosphines | CYP1A1, NR5A1, AR | TLR8 4282/4885GAA 3491/4885ALDH1A1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.